Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 4;9:14299. doi: 10.1038/s41598-019-50528-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Microphotographs (×40) from tumor and tumor-adjacent, non-cancerous samples. (a) NF-κB2 in a grade II, squamous lung carcinoma with strong and intermediate cytoplasmic staining without nuclear signal, (b) NF-κB2 intermediate cytoplasmic staining in adenocarcinoma, (c) strong and intermediate cytoplasmic signal for NF-κB2 in an undifferentiated large-cell carcinoma, (d) negative immunostaining for NF-κB2 protein in alveolar epithelium and interstitium of tumor-adjacent non-neoplastic lung parenchyma, (e) RelB immunodetection in a grade III, squamous-cell carcinoma with strong cytoplasmic staining, (f) strong nuclear and cytoplasmic staining for RelB protein in grade III lung adenocarcinoma, (g) representative section of undifferentiated large-cell, lung carcinoma with strong cytoplasmic signal for RelB, (h) negative immunostaining for RelB in alveolar epithelium and interstitium of tumor-adjacent non-neoplastic lung parenchyma from a squamous-cell carcinoma, (i) representative section from a grade I, squamous -cell carcinoma with strong cytoplasmic staining for NIK, (j) intermediate cytoplasmic staining for NIK in an adenocarcinoma, (k) strong cytoplasmic immunostaining for NIK in large-cell lung carcinoma, (l) negative immunostaining for ΝΙΚ in alveolar epithelium and interstitium of adjacent non-neoplastic lung parenchyma from a large-cell carcinoma, (m) representative section of grade I, squamous-cell carcinoma with strong cytoplasmic and intermediate nuclear staining for Bcl3, (n) strong cytoplasmic staining for Bcl3 in a lung adenocarcinoma, (o) intermediate nuclear and strong cytoplasmic staining for Bcl3 protein in a large-cell lung carcinoma, (p) negative immunostaining for Bcl3 in alveolar epithelium of tumor-adjacent, non-neoplastic lung parenchyma.